Indian pharmaceutical company Zydus Cadila has acquired two abbreviated new drug applications (ANDAs) from Israeli-American pharmaceutical company Teva.

The two ANDAs are being sold out by Teva as a pre-condition to its acquisition of pharmaceutical company Allergan‘s generic business.

Headquartered in Ahmadabad, India, Zydus has taken over the two Teva ANDAs through its wholly-owned subsidiary Zydus Worldwide DMCC in Dubai.

Financial details of the transaction will be financed through the group’s internal accruals and have not been disclosed.

"Zydus is upbeat about the growth potential in the US and will continue to pursue more inorganic opportunities in the US market."

The acquisition includes an ANDA that is already commercialised and one pipeline ANDA, which is a transdermal patch.

According to the Zydus Group chairman and managing director Pankaj R. Patel, the acquisition will play a primary role in helping the company expand its existing portfolio in the US, as well as in strengthening its pipeline of complex generic products.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Pankaj R. Patel said: "Zydus is upbeat about the growth potential in the US and will continue to pursue more inorganic opportunities in the US market."

Zydus Group has made substantial investments in the transdermal manufacturing technology.

The company also acquired a transdermal manufacturing facility in the US a few years previously.

Zydus Cadila employs more than 19,000 people worldwide and discovers, manufactures and markets a wide range of healthcare therapies.